TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy

Critical Role for CD103 + /CD141 + Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma

(2016) Edward W. Roberts et al.   CANCER CELL

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition

(2016) Hélène Salmon et al.   IMMUNITY

The host STING pathway at the interface of cancer and immunity

(2016) Leticia Corrales et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting TYRO3 inhibits epithelial–mesenchymal transition and increases drug sensitivity in colon cancer

(2016) C-W Chien et al.   ONCOGENE

The TAM family receptor tyrosine kinase TYRO3 is a negative regulator of type 2 immunity

(2016) P. Y. Chan et al.   SCIENCE

Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy

(2016) Marka R. Crittenden et al.   Oncotarget

TAM Receptor Signaling in Immune Homeostasis

(2015) Carla V. Rothlin et al.   Annual Review of Immunology

Macrophages and Therapeutic Resistance in Cancer

(2015) Brian Ruffell et al.   CANCER CELL

Expanding the clinical, allelic and locus heterogeneity of retinal dystrophies

(2015) Nisha Patel et al.   GENETICS IN MEDICINE

Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status

(2015) C. T. Cummings et al.   MOLECULAR CANCER THERAPEUTICS

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Amino acid auxotrophy as a system of immunological control nodes

(2015) Peter J Murray   NATURE IMMUNOLOGY

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT

(2015) D N Debruyne et al.   ONCOGENE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

T cell metabolic fitness in antitumor immunity

(2015) Peter J. Siska et al.   TRENDS IN IMMUNOLOGY

T cell exhaustion during persistent viral infections

(2015) Shannon M. Kahan et al.   VIROLOGY

Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia

(2015) Alisa B. Lee-Sherick et al.   Oncotarget

Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer

(2015) Christopher T. Cummings et al.   Oncotarget

CD8+ Tumor-Infiltrating T Cells Are Trapped in the Tumor-Dendritic Cell Network

(2015) Alexandre Boissonnas et al.   NEOPLASIA

Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity

(2014) Miranda L. Broz et al.   CANCER CELL

B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer

(2014) Scott Gettinger et al.   CANCER JOURNAL

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

(2014) Seng-Ryong Woo et al.   IMMUNITY

Tumor-Associated Macrophages: From Mechanisms to Therapy

(2014) Roy Noy et al.   IMMUNITY

Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution

(2014) Jamie C. Stanford et al.   JOURNAL OF CLINICAL INVESTIGATION

UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor

(2014) Weihe Zhang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

Tim4- and MerTK-Mediated Engulfment of Apoptotic Cells by Mouse Resident Peritoneal Macrophages

(2014) C. Nishi et al.   MOLECULAR AND CELLULAR BIOLOGY

Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer

(2014) Maurizio Callari et al.   Molecular Oncology

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

(2014) Mahesh Yadav et al.   NATURE

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells

(2014) Magdalena Paolino et al.   NATURE

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Galectins CLIC cargo inside

(2014) Pamela Stanley   NATURE CELL BIOLOGY

An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis

(2014) Mihalis S Kariolis et al.   Nature Chemical Biology

Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival

(2013) F. Bertucci et al.   ANNALS OF ONCOLOGY

Evaluation of Tyro3 Expression, Gas6-Mediated Akt Phosphorylation, and the Impact of Anti-Tyro3 Antibodies in Melanoma Cell Lines

(2013) Stephen J. Demarest et al.   BIOCHEMISTRY

Inhibitory role of Gas6 in intestinal tumorigenesis

(2013) Reiko Akitake-Kawano et al.   CARCINOGENESIS

T Cell-Derived Protein S Engages TAM Receptor Signaling in Dendritic Cells to Control the Magnitude of the Immune Response

(2013) Eugenio A. Carrera Silva et al.   IMMUNITY

NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors

(2013) Paul Spear et al.   IMMUNOLOGY AND CELL BIOLOGY

MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis

(2013) Rebecca S. Cook et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

(2013) Jason R Westin et al.   LANCET ONCOLOGY

Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib

(2013) Keith M. Giles et al.   MOLECULAR CANCER THERAPEUTICS

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

(2013) Paul F Robbins et al.   NATURE MEDICINE

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy

(2013) W Leconet et al.   ONCOGENE

Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer

(2013) L. Bosurgi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells

(2013) A. S. Meyer et al.   Science Signaling

Biology of the TAM Receptors

(2013) G. Lemke   Cold Spring Harbor Perspectives in Biology

Phosphatidylserine-Targeting Antibody Induces M1 Macrophage Polarization and Promotes Myeloid-Derived Suppressor Cell Differentiation

(2013) Y. Yin et al.   Cancer Immunology Research

The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer

(2012) A Popple et al.   BRITISH JOURNAL OF CANCER

Marginating Dendritic Cells of the Tumor Microenvironment Cross-Present Tumor Antigens and Stably Engage Tumor-Specific T Cells

(2012) John J. Engelhardt et al.   CANCER CELL

Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas

(2012) Muhammad Baghdadi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Autozygome-guided exome sequencing in retinal dystrophy patients reveals pathogenetic mutations and novel candidate disease genes

(2012) L. Abu-Safieh et al.   GENOME RESEARCH

F-Actin Is an Evolutionarily Conserved Damage-Associated Molecular Pattern Recognized by DNGR-1, a Receptor for Dead Cells

(2012) Susan Ahrens et al.   IMMUNITY

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

(2012) Shigeki Chiba et al.   NATURE IMMUNOLOGY

Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages

(2012) Emmanuel L Gautier et al.   NATURE IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines

(2012) A N Rettew et al.   Oncogenesis

Epithelial cell-directed efferocytosis in the post-partum mammary gland is necessary for tissue homeostasis and future lactation

(2011) Melissa Sandahl et al.   BMC DEVELOPMENTAL BIOLOGY

A signature of immune function genes associated with recurrence-free survival in breast cancer patients

(2011) Maria Libera Ascierto et al.   BREAST CANCER RESEARCH AND TREATMENT

The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma

(2011) Alvarez Hector et al.   CANCER BIOLOGY & THERAPY

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control

(2011) M. Hong et al.   CANCER RESEARCH

The role of macrophages and dendritic cells in the clearance of apoptotic cells in advanced atherosclerosis

(2011) Edward Thorp et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Homozygous Mutation in MERTK Causes Severe Autosomal Recessive Retinitis Pigmentosa

(2011) Mohamed Ksantini et al.   EUROPEAN JOURNAL OF OPHTHALMOLOGY

Galectin-3 is a new MerTK-specific eat-me signal

(2011) Nora B. Caberoy et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells

(2011) Mercedes B. Fuertes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

(2011) Mark S. Diamond et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Human Cutaneous Melanomas Lacking MITF and Melanocyte Differentiation Antigens Express a Functional Axl Receptor Kinase

(2011) Marialuisa Sensi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells

(2011) Kim J. Png et al.   NATURE

Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology

(2011) A E J Rogers et al.   ONCOGENE

The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy

(2010) A. K. Ghosh et al.   BLOOD

R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer

(2010) S. J. Holland et al.   CANCER RESEARCH

Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis

(2010) Nora B Caberoy et al.   EMBO JOURNAL

Proinflammatory Clearance of Apoptotic Neutrophils Induces an IL-12lowIL-10high Regulatory Phenotype in Macrophages

(2010) A. A. Filardy et al.   JOURNAL OF IMMUNOLOGY

Potentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization

(2010) J. M. E. M. COSEMANS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies

(2010) X Ye et al.   ONCOGENE

Correlation of CXCL12 Expression and FoxP3 + Cell Infiltration with Human Papillomavirus Infection and Clinicopathological Progression of Cervical Cancer

(2009) Fatimah Jaafar et al.   AMERICAN JOURNAL OF PATHOLOGY

Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment

(2009) H. Harlin et al.   CANCER RESEARCH

Antiphosphatidylserine Antibody Combined with Irradiation Damages Tumor Blood Vessels and Induces Tumor Immunity in a Rat Model of Glioblastoma

(2009) J. He et al.   CLINICAL CANCER RESEARCH

Biomolecular Network Reconstruction Identifies T-Cell Homing Factors Associated With Survival in Colorectal Cancer

(2009) Bernhard Mlecnik et al.   GASTROENTEROLOGY

Milk fat globule epidermal growth factor–8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms

(2009) Masahisa Jinushi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Identification of a dendritic cell receptor that couples sensing of necrosis to immunity

(2009) David Sancho et al.   NATURE

Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis

(2009) Y Li et al.   ONCOGENE

A genomic screen identifies TYRO3 as a MITF regulator in melanoma

(2009) S. Zhu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous Malignancy

(2008) Nadia Guerra et al.   IMMUNITY

Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin

(2008) David Sancho et al.   JOURNAL OF CLINICAL INVESTIGATION

NK cells and cancer immunosurveillance

(2008) I Waldhauer et al.   ONCOGENE

Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity

(2008) K. Hildner et al.   SCIENCE